文献速递胸部肿瘤放疗放疗物理与技术

肺癌质子与光子放疗成本分析的可适配框架:荷兰社会视角与医疗视角

Adaptable framework for cost-analyses in radiotherapy: Application to the cost of proton versus photon therapy for lung cancer in The Netherlands.
PubMed 文献 · Radiother Oncol · 2025-03-08

该研究依据荷兰成本核算指南,构建从首次转诊至治疗结束的概率性成本分析框架,并应用于肺癌质子放疗与光子放疗。社会视角下质子放疗固定成本为11208欧元、光子放疗为9651欧元,每分次可变成本分别为932欧元与265欧元,20分次方案总成本比为2.00。研究强调通用参数与中心特异性参数可导致成本差异。

要点

  • 社会视角固定成本:质子放疗11208欧元,光子放疗9651欧元。
  • 每分次可变成本:质子放疗932欧元,光子放疗265欧元。
  • 20分次总成本比2.00,30分次为2.23。

核心结论

  • 研究开发了一个用于概率性成本分析的可适配框架,结果凸显质子放疗与光子放疗之间的成本差异,并为未来成本效果分析提供信息。
  • 情景分析显示临床经验与容量提升可能缩小差异。
  • 平行基线分析凸显使用通用参数与中心特异性参数时产生的成本差异,以及中心间潜在的结果差异。

研究设计与样本

  • 遵循荷兰成本核算指南,估算从首次转诊至治疗结束的成本。
  • 开展平行基线分析,以中心特异性参数替代通用参数。
  • 采用蒙特卡洛模拟(10000次迭代)进行概率性成本计算,成本分为医疗(人员、非人员)、患者/家庭及其他部门三类。
  • 直接医疗人员成本采用时间驱动作业成本法估算,以区分非分次依赖成本。
  • 进一步开展敏感性与情景分析。

主要发现

  • 社会视角固定成本:质子放疗11208欧元,光子放疗9651欧元。
  • 每分次可变成本:质子放疗932欧元,光子放疗265欧元。
  • 20分次方案质子放疗与光子放疗总成本比为2.00,30分次方案为2.23。
  • 质子放疗相对于光子放疗的最大增量成本驱动类别为非直接人员医疗成本(管理费用、资本支出)。

关键数值与推荐

  • 社会视角固定成本(指南分析均值):质子放疗11208欧元,光子放疗9651欧元。
  • 社会视角固定成本(中心特异性分析均值):质子放疗12299欧元,光子放疗10977欧元。
  • 每分次可变成本(指南分析均值):质子放疗932欧元,光子放疗265欧元。
  • 每分次可变成本(中心特异性分析均值):质子放疗798欧元,光子放疗265欧元。
  • 总成本比(质子放疗/光子放疗):20分次方案指南分析2.00、中心特异性分析1.74;30分次方案指南分析2.23、中心特异性分析1.91。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: Proton radiation-therapy (PrT) may provide clinical benefit for lung cancer compared to photon radiation-therapy (PhT), however is more costly. Literature reporting costs for PrT, PhT, and comparisons thereof, particularly from a societal perspective, are scarce. This study aims to provide an adaptable framework to estimate PrT/PhT costs, demonstrated through application to lung cancer, from societal and healthcare perspectives. METHODS: Dutch Costing Guidelines were followed to estimate costs from first referral to end of treatment. A parallel base-case was conducted whereby centre-specific inputs replaced general input parameters. Costs were calculated probabilistically using Monte Carlo simulations (10,000 iterations) and separated into three categories: healthcare (subdivided: personnel, non-personnel), patient/family, and costs in other sectors. Direct healthcare personnel costs were estimated using time-driven activity-based costing, allowing separation of non-fraction-dependant costs. Further sensitivity/scenario analyses were explored. RESULTS: Fixed costs (guideline[centre-specific] analyses mean) from a societal perspective were €11,208[€12,299] for PrT and €9,651[€10,977] for PhT. Variable costs per fraction were €932[€798] for PrT and €265[€265] for PhT. Total cost ratio for PrT to PhT was 2.00[1.74] for 20 fraction schedules and 2.23[1.91] for 30 fractions. The greatest incremental cost driver category for PrT versus PhT was non-(direct)personnel healthcare costs (overheads, capital outlays). CONCLUSION: An adaptable framework for probabilistic cost-analyses was developed. Results highlight cost disparities between PrT and PhT and serves to inform future cost-effectiveness analyses. Scenarios reveal potential for clinical experience and increased capacity to narrow differences. Parallel base-case analyses highlight cost disparities arising when utilising generic vs centre-specific inputs, and potential outcome differences between centres.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sugden BM, Witlox WJA, Ramaekers BLT, et al. Adaptable framework for cost-analyses in radiotherapy: Application to the cost of proton versus photon therapy for lung cancer in The Netherlands. Radiother Oncol. 2025. PMID: 40058706. doi:10.1016/j.radonc.2025.110832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。